Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Iterum Therapeutics ( (ITRM) ) has issued an update.
On February 24, 2026, Iterum Therapeutics received a delisting determination from Nasdaq after failing to maintain the $1.00 minimum bid price, and on March 3, 2026, the company requested a hearing before a Nasdaq Hearings Panel, which temporarily stayed any suspension or delisting. Iterum also remains out of compliance with Nasdaq’s minimum market value and other financial standards and must show by June 9, 2026 that it can regain and sustain compliance, while simultaneously evaluating strategic options including potential asset sales, wind-down, or bankruptcy, outcomes that could leave shareholders with little or no recovery.
The company disclosed that its limited ability to raise capital and constrained time and resources may hinder its capacity to execute any strategic transaction or restructuring. This heightened delisting risk and the prospect of a possible liquidation or similar proceeding underscore significant uncertainty for investors, as there is no assurance that any strategic alternative will be completed or that any meaningful value will be preserved for equity holders.
The most recent analyst rating on (ITRM) stock is a Hold with a $0.31 price target. To see the full list of analyst forecasts on Iterum Therapeutics stock, see the ITRM Stock Forecast page.
Spark’s Take on ITRM Stock
According to Spark, TipRanks’ AI Analyst, ITRM is a Neutral.
The score is held down primarily by weak financial fundamentals (minimal revenue, persistent losses, cash burn, and negative equity) and bearish technicals (price below major moving averages with negative MACD). The earnings call adds some support due to early launch traction and 2026 revenue guidance, but this is tempered by the need for additional capital, while the Nasdaq listing compliance issue adds further downside risk.
To see Spark’s full report on ITRM stock, click here.
More about Iterum Therapeutics
Iterum Therapeutics plc is a biopharmaceutical company focused on developing anti-infective treatments, with its primary activities centered on advancing specialty pharmaceutical assets through clinical and regulatory pathways. The company operates in a capital-intensive segment of the healthcare sector, where maintaining access to public equity markets is critical for funding ongoing operations and strategic initiatives.
Average Trading Volume: 790,580
Technical Sentiment Signal: Sell
Current Market Cap: $14.92M
For a thorough assessment of ITRM stock, go to TipRanks’ Stock Analysis page.